[1]刘立宁,周玮,侯楠,等.清热除痹汤治疗湿热痹阻型急性痛风性关节炎的临床观察[J].中国中医骨伤科杂志,2023,31(11):47-50.[doi:10.20085/j.cnki.issn1005-0205.231109]
　LIU Lining,ZHOU Wei,HOU Nan,et al.Clinical Observation on the Treatment of Acute Gouty Arthritis of Damp-Heat Arthralgia Type by Qingre Chubi Decoction[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2023,31(11):47-50.[doi:10.20085/j.cnki.issn1005-0205.231109]
点击复制

清热除痹汤治疗湿热痹阻型急性痛风性关节炎的临床观察()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第31卷
期数:
2023年11期
页码:
47-50
栏目:
临床研究
出版日期:
2023-11-15

文章信息/Info

Title:
Clinical Observation on the Treatment of Acute Gouty Arthritis of Damp-Heat Arthralgia Type by Qingre Chubi Decoction
文章编号:
1005-0205(2023)11-0047-04
作者:
刘立宁1; 周玮1; 侯楠1; 刘一帆1△
1聊城市人民医院风湿免疫科(山东 聊城,252000)
Author(s):
LIU Lining1; ZHOU Wei1; HOU Nan1; LIU Yifan1△
1Department of Rheumatology and Immunology,Liaocheng People's Hospital,Liaocheng 252000,Shandong China.
关键词:
清热除痹汤;  痛风性关节炎;  中医证候积分;  尿酸;  辅助性T细胞
Keywords:
Qingre Chubi decoction;  gouty arthritis;  TCM syndrome score;  uric acid;  helper T cells
分类号:
R684.3
DOI:
10.20085/j.cnki.issn1005-0205.231109
文献标志码:
A
摘要:
目的:探讨清热除痹汤在湿热痹阻型急性痛风性关节炎治疗中的应用效果。方法:选取2019年5月至2022年5月湿热痹阻型急性痛风性关节炎患者86例,采用随机数字表法分为B组(43例)和A组(43例)。A组患者接受依托考昔治疗,B组患者接受清热除痹汤治疗,比较两组患者治疗前后中医证候积分、红细胞沉降率(ESR)、C-反应蛋白(CRP)、血尿酸(UA)、干扰素-γ(IFN-γ)、白介素-4(IL-4)水平,统计两组患者疗效及不良反应发生情况。结果:两组患者疗效比较差异无统计学意义(P>0.05); 治疗后,两组患者中医证候积分、红细胞沉降率、C-反应蛋白、血尿酸、干扰素-γ、IFN-γ/IL-4水平均降低,两组患者IL-4水平均升高,差异有统计学意义(P<0.05),组间对比差异无统计学意义(P>0.05); B组患者不良反应发生率低于A组患者,差异有统计学意义(P<0.05)。结论:清热除痹汤治疗湿热痹阻型急性痛风性关节炎,能取得与依托考昔相似疗效,且安全性较高。
Abstract:
Objective:To investigate the application efficacy of Qingre Chubi decoction on the treatment of acute gouty arthritis patients with damp-heat arthralgia.Methods:86 patients with damp-heat arthralgia type acute gouty arthritis who were admitted from May 2019 to May 2022 were selected as the research objects,and they were randomly divided into the group B of 43 cases and group A of 43 cases.Group A was received toricoxib treatment,and the group B was received Qingre Chubi decoction treatment.The traditional Chinese medicine(TCM)syndrome scores,erythrocyte sedimentation rate(ESR),levels of C-reactive protein(CRP),serum uric acid(UA),interferon-γ(IFN-γ)and interleukin-4(IL-4)before and after treatment were compared between the two groups,the efficacy and occurrence of adverse reactions were counted.Results:There was no significant difference in efficacy between the two groups(P>0.05).After treatment,the TCM evidence score,ESR,CRP,UA,IFN-γ and IFN-γ/IL-4 levels decreased in both groups,and IL-4 levels increased in both groups,with no significant difference between the groups(P>0.05).The incidence of adverse reactions in group B was lower than that in group A(P<0.05).Conclusion:Qingre Chubi decoction has significant efficacy on the treatment of acute gouty arthritis patients with damp-heat obstruction type,which can effectively relieve clinical symptoms,and has high safety.

参考文献/References:

[1] 王仁崇,蒋电明,黄伟,等.痛风性关节炎的研究进展[J].中华风湿病学杂志,2011,15(9):647-650.
[2] 杨丽华,刘晓丽,蒋雅琼,等.我国痛风的患病率及危险因素[J].医学研究杂志,2019,48(12):4-6.
[3] 刘婷,张霞,李飞燕.急性痛风性关节炎的中西医治疗进展[J].中国中医急症,2019,28(2):374-376.
[4] NEOGI T,JANSEN T L,DALBETH N,et al.2015 Gout classification criteria:an American college of rheumatology/European league against rheumatism collaborative initiative[J].Arthritis Rheumatol,2015,67(10):2557-2568.
[5] 国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:349-353.
[6] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994:72.
[7] 郭军强.正清风痛宁片联合非布司他治疗痛风性关节炎的作用机制分析[J].临床研究,2019,27(3):118-119.
[8] 舒建龙,李凤珍,覃裕旺.痛风病理及临床中西医治疗的研究进展[J].中国实验方剂学杂志,2020,26(2):218-227.
[9] 李刘坤.吴鞠通医学全书[M].北京:中国中医药出版社,2005:65-66.
[10] 劳贝妮,孙维峰,李静.清热除痹汤治疗急性痛风疗效及安全性评价[J].广州中医药大学学报,2016,33(6):794-799.
[11] 陈铎葆,徐冰,李兵,等.寻骨风对抗炎镇痛作用的研究[J].基层中药杂志,2001,15(1):9-10.
[12] 韦健全,罗莹,黄健,等.穿破石抗炎镇痛活性观察及最大给药量测定[J].中成药,2011,33(9):1589-1592.
[13] 张洪长,刘明昕,张莹,等.青藤碱对类风湿关节炎成纤维样滑膜细胞MyD88、TRAF-6表达的影响[J].中国免疫学杂志,2015,31(4):485-489.
[14] DESAI J,STEIGER S,ANDERS H J.Molecular pathophysiology of gout[J].Trends Mol Med,2017,23(8):756-768.
[15] 贺明玉,刘健,韩馨悦,等.痛风性关节炎患者免疫指标的变化及中医药干预的数据挖掘研究[J].风湿病与关节炎,2019,8(10):9-13.
[16] HARRE U,DERER A,SCHORN C,et al.T cells as key players for bone destruction in gouty arthritis[J].Arthritis Res Ther,2011,13(6):135.
[17] TONG J,HU X J,CAI W Q,et al.Puerarin alleviates delayed-type hypersensitivity via cytokine inhibition by modulating Th1/Th2 balance[J].Exp Ther Med,2018,15(5):4441-4447.
[18] ZHU X,ZHU J.CD4 T helper cell subsets and related human immunological disorders[J].Int J Mol Sci,2020,21(21):8011.

备注/Memo

备注/Memo:
基金项目:山东省中医药科技项目(2021Q010)
△通信作者 E-mail:ban302265@163.com
更新日期/Last Update: 2023-11-01